Current report 35/2021 – Summary of subscription of ordinary D-series bearer shares in Celon Pharma S.A.

Current reports July 29, 2021

Management Board of Celon Pharma S.A. _”The Company”_ provides information regarding the completed subscription nominal value of PLN 0.1 each. nominal value of PLN 0.1 each. _”Offered Shares”_ held pursuant to Resolution No. 4 of the Extraordinary General Meeting of the Company of February 16, 2021 _current report 9/2021_ and the resolution on the share capital increase under the authorized capital adopted by the Management Board of the Company on May 10, 2021. _current report 22/2021_, as amended by a resolution of the Management Board of the Company of May 25, 2021. _current report 29/2021_:

Celon Pharma S.A. launches public offering of D-series shares

Press Materials July 1, 2021

On 01 July 2021 Celon Pharma S.A. received the decision on approval of the prospectus by the Polish Financial Supervision Authority and published its prospectus in connection with its public offering of D-series shares (the “Offering”). The maximum price in the Offering was set at PLN 45 per share. The Company intends to issue up to 6,000,000 shares and obtain EUR 60 million to finance development of its clinical pipeline and for other corporate purposes, over the course of the next two years.